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Abstract
Background: Previous research has shown that Short Psychodynamic Supportive Psychotherapy
(SPSP) is an effective alternative to pharmacotherapy and combined treatment (SPSP and
pharmacotherapy) in the treatment of depressed outpatients. The question remains, however, how
Short Psychodynamic Supportive Psychotherapy compares with other established psychotherapy
methods. The present study compares Short Psychodynamic Supportive Psychotherapy to the
evidence-based Cognitive Behavioral Therapy in terms of acceptability, feasibility, and efficacy in the
outpatient treatment of depression. Moreover, this study aims to identify clinical predictors that
can distinguish patients who may benefit from either of these treatments in particular. This article
outlines the study protocol. The results of the study, which is being currently carried out, will be
presented as soon as they are available.
Methods/Design: Adult outpatients with a main diagnosis of major depressive disorder or
depressive disorder not otherwise specified according to DSM-IV criteria and mild to severe
depressive symptoms (Hamilton Depression Rating Scale score ≥ 14) are randomly allocated to Short
Psychodynamic Supportive Psychotherapy or Cognitive Behavioral Therapy. Both treatments are
individual psychotherapies consisting of 16 sessions within 22 weeks. Assessments take place at
baseline (week 0), during the treatment period (week 5 and 10) and at treatment termination
(week 22). In addition, a follow-up assessment takes place one year after treatment start (week 52).
Primary outcome measures are the number of patients refusing treatment (acceptability); the
number of patients terminating treatment prematurely (feasibility); and the severity of depressive
symptoms (efficacy) according to an independent rater, the clinician and the patient. Secondary
outcome measures include general psychopathology, general psychotherapy outcome, pain, health-
related quality of life, and cost-effectiveness. Clinical predictors of treatment outcome include
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BMC Psychiatry 2007, 7:58 http://www.biomedcentral.com/1471-244X/7/58demographic variables, psychiatric symptoms, cognitive and psychological patient characteristics
and the quality of the therapeutic relationship.
Discussion: This study evaluates Short Psychodynamic Supportive Psychotherapy as a treatment
for depressed outpatients by comparing it to the established evidence-based treatment Cognitive
Behavioral Therapy. Specific strengths of this study include its strong external validity and the
clinical relevance of its research aims. Limitations of the study are discussed.
Trial registration: Current Controlled Trails ISRCTN31263312
Background
Depressive disorders constitute a major health problem in
today's world. According to the World Health Organiza-
tion, in the year 2000 depressive disorders were the lead-
ing cause of disability around the world and the fourth
leading contributor to the global burden of disease. It is
estimated that by the year 2020 depression will comprise
the world's second largest disease burden, second only to
ischemic heart disease [1]. Currently, more than 150 mil-
lion people around the world are suffering from a depres-
sion [2]. Consequently, there is a high need for effective
treatment.
The efficacy of existing psychotherapies for depressive dis-
orders was recently reviewed by Roth & Fonagy [3]. They
conclude that in general psychotherapy is an effective
treatment of depression when compared to placebo. Cog-
nitive Behavioral Therapy (CBT), Interpersonal Psycho-
therapy (IPT), Problem Solving Therapy (PST), couple
therapy, bibliotherapy, and computer-aided therapy all
have shown to be effective treatment methods, consist-
ently efficacious in around 50–60% of cases. In contrast,
there still is limited evidence base for brief dynamic ther-
apy, although this form of treatment is widely applied in
clinical practice. According to Roth & Fonagy, the results
of the few available studies on brief dynamic therapy are
flawed by methodological problems and a probable bias
due to investigator alliance. The outcomes of good-quality
trials, they conclude, suggest effectiveness equal to the
psychotherapies mentioned above, but the conclusions
that can be drawn about this treatment method are
severely limited by the paucity of trials. This view is shared
by the Cochrane reviewers of short-term psychodynamic
therapies for common mental disorders [4]. They find
modest to moderate gains of brief dynamic therapy for a
variety of patients, but also conclude that these findings
should be interpreted with caution because of limited
data. Due to the scarcity of studies, the authors cannot
draw any conclusions about the efficacy for depressed
patients specifically. The present study aims at contribut-
ing to the gap in knowledge on this subject by comparing
Short Psychodynamic Supportive Psychotherapy (SPSP)
and Cognitive Behavioral Therapy in the treatment of
depressed outpatients.
Short Psychodynamic Supportive Psychotherapy [5,6]
was developed in the early 90's as a structured psychody-
namically orientated treatment for depressed outpatients
within JellinekMentrum Mental Health Care Amsterdam
(JMHC). Since then the acceptability, feasibility, and effi-
cacy of this treatment have been compared to pharmaco-
therapy and combined treatment (SPSP and
pharmacotherapy) in four randomized clinical trials [7-
10]. In these studies, treatment acceptability is conceptu-
alized by the number of patients refusing treatment when
allocated to it by study randomization. Feasibility is the
number of patients who terminate treatment prematurely.
Efficacy refers to the number of patients recovered from
depressive symptoms according to an independent
observer, the patient and the therapist.
De Maat et al. [11] performed a 'mega-analysis' on the
data of the first three trials, in which the effects of SPSP,
pharmacotherapy, and combined treatment were com-
pared both in terms of symptom reduction and quality of
life improvement. The results suggest that the combina-
tion of SPSP and pharmacotherapy is more efficacious
than pharmacotherapy alone. Besides patients finding
combined therapy more efficacious in reducing depressive
symptoms, no difference in efficacy was found when com-
paring SPSP and combined therapy. SPSP and pharmaco-
therapy were found to be equally efficacious, except for
some indications that patients and therapists favor SPSP
with regard to symptom reduction. The results of the
above-mentioned trials further indicate a better accepta-
bility of SPSP compared to both pharmacotherapy and
combined treatment [8,10]; fewer patients refuse SPSP
because there is no medication involved. With regard to
the feasibility, no differences were found [11].
In sum, previous research suggests that, while the combi-
nation of SPSP and pharmacotherapy seems to work bet-
ter than pharmacotherapy alone, the superiority of
combined treatment to SPSP is less obvious. In addition,
SPSP and pharmacotherapy seem to be equally effica-
cious. Furthermore, the trial results provide support for
the acceptability and feasibility of SPSP as an alternative
treatment for depressed outpatients. Although combined
treatment appears to be more efficacious than SPSP alone,Page 2 of 14
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because of the required medication. Therefore SPSP might
be a treatment of first choice for a great deal of depressed
outpatients.
As mentioned earlier, so far SPSP has been compared to
either pharmacotherapy or combined treatment. How-
ever, the question remains how SPSP compares with
another established form of psychotherapy. Therefore the
present study seeks to compare the acceptability, feasibil-
ity, and efficacy of SPSP to CBT, which is an evidence-
based psychotherapy for the treatment of depressive dis-
orders [3]. In addition, it is unclear whether there are spe-
cific groups of patients, who might benefit from one of
these treatments in particular. This study aims to gain
more insight into this issue as well.
Research aims
The aim of this study is twofold. First, the research com-
pares Short Psychodynamic Supportive Psychotherapy
and Cognitive Behavioral Therapy in terms of acceptabil-
ity, feasibility, and efficacy. Second, it seeks to identify
clinical predictors that distinguish patients that can bene-
fit from either of these treatments in particular. These clin-
ical predictors include demographic variables,
(comorbid) psychiatric symptoms, cognitive and psycho-
logical patient characteristics, and the quality of the ther-
apeutic alliance.
Hypotheses
Considering the first research aim, it is hypothesized that
both treatments will be equally efficacious. This is based
on Roth and Fonagy's [3] conclusions described above. In
line with the earlier trials, it is further hypothesized that
both psychotherapies will be equally acceptable and feasi-
ble to patients as well, since neither includes the use of
medication.
With regard to the second aim, it is expected that a predic-
tive relationship will be found between patient character-
istics and the efficacy of one of the two treatments in
particular. Because systematic research on other predictive
patient characteristics is relatively scarce, only three
hypotheses are formulated. Though based on a small
dataset, Van et al. [12] found that a subgroup of patients
with comorbid symptoms of anxiety benefited less from
SPSP. It is hypothesized that CBT will be more effective for
this group of patients, because CBT is generally consid-
ered to be the treatment of choice for anxiety disorders. In
addition, it is hypothesized that patients with comorbid
personality disorders may benefit more from SPSP. While
these patients are usually regarded as difficult to treat,
SPSP showed positive treatment effects when combined
with pharmacotherapy in a subgroup of depressed
patients with comorbid personality pathology [13]. Fur-
thermore, it is thought that patients showing a higher
degree of dysfunctional attitudes or cognitive reactivity to
sad mood might respond better to CBT, because CBT spe-
cifically attends to these cognitive aspects.
Methods/Design
Design
This study is a randomized controlled trial comparing the
acceptability, feasibility, and efficacy of Short Psychody-
namic Supportive Psychotherapy (SPSP) and Cognitive
Behavioral Therapy (CBT) in the treatment of depression.
Participants are randomly allocated to either the SPSP or
CBT treatment condition. Participants receive pharmaco-
therapy in addition to their psychotherapy if they show
severe depressive symptoms at baseline assessment (Ham-
ilton Depression Rating Scale [14,15]; HDRS score > 24).
The main outcome measure is the number of patients
with depressive symptoms in remission (HDRS score ≤ 8)
at the termination of psychotherapy at week 22. In case of
remaining depressive symptomatology at the termination
of psychotherapy treatment (HDRS score ≥ 12 at week 22)
patients will receive care as usual according to the Jellinek-
Mentrum Mental Health Care regular procedures. This
usually consists of additional pharmacotherapy as
described in more detail later.
Participants/Setting
Participants are adult outpatients referred to one of three
JellinekMentrum Mental Health Care (JMHC) clinics by
their general practitioner on account of psychiatric com-
plaints. These three mental health clinics are located in
the city centre, the northern part, and the western part of
Amsterdam (the Netherlands). It is therefore assumed
that these clinics attend to a heterogeneous group of
inhabitants.
Inclusion criteria are a main diagnosis of major depressive
disorder or depressive disorder not otherwise specified
(NOS), with or without a dysthymic disorder, according
to DSM-IV criteria [16], mild to severe depressive symp-
toms (HDRS score ≥ 14 at base line), age between 18 and
65 years, and written informed consent.
Exclusion criteria are the presence of psychotic symptoms
or a bipolar disorder, use of antidepressants, risk of sui-
cide or loss of impulse control, substance misuse or abuse
within the last six months (use of hard drugs, use of can-
nabis more than three times a week or alcohol above 21
units a week), use of antipsychotics or mood stabilizers,
use of benzodiazepines (equivalent to more than 30 mg
oxazepam per week), and use of medication that influ-
ences mental functions. Patients are also excluded from
the trial if they are pregnant, not able to fill in the ques-
tionnaires because of language problems or physical diffi-
culties, absent for more than three weeks during thePage 3 of 14
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trial. Patients who were in contact with the same clinic
within the last six months or participated in another
depression research project within the last year cannot
take part in the study either.
Procedure
All patients referred to one of the three JMHC clinics are
screened at intake by a psychiatrist and a psychologist for
the presence of a depressive disorder and the absence of
exclusion criteria. Eligible patients are invited for baseline
assessment within one week after intake.
At the baseline assessment, inclusion and exclusion crite-
ria are checked again, the research goals are explained, and
information about participation in the research project is
provided. Patients willing to participate sign an informed
consent. Subsequently, the Mini-International Neuropsychi-
atric Interview – Plus (MINI-Plus) [17] and the Hamilton
Depression Rating Scale (HDRS-17) [14,15] are conducted
to confirm the presence of a depressive disorder and to
determine the depression severity. Patients with a MINI-
Plus diagnosis of depressive disorder and HDRS score of
14 or above are included in the study. They are randomly
allocated to one of the psychotherapies, which are
described in more detail in the next section, and are asked
to fill in the questionnaires for the baseline measurement
(see Table 1 for an overview).
Within two weeks after the baseline measurement, psy-
chotherapy starts. Participants with severe depressive
symptoms (HDRS score > 24), who receive additional
pharmacotherapy, have an appointment with a psychia-
trist first. Assessments take place during the treatment
period (week 5 and 10) and at treatment termination
(week 22). In addition, participants are invited for a fol-
low-up assessment one year after the start of treatment
(week 52). At these assessments participants fill in ques-
tionnaires and the HDRS-17 is conducted by the inde-
pendent assessor.
Table 1 gives an overview of the interviews and question-
naires conducted at the different assessment times. Figure
1 represents the research procedure schematically. Figure
2 contains the expected participant flow.
Interventions
Participants are randomly allocated to either Short Psy-
chodynamic Supportive Psychotherapy (SPSP) or Cogni-
tive Behavioral Therapy (CBT). Both are individual
psychotherapies encompassing 16 sessions within 22
weeks. The first ten sessions take place weekly; the final six
sessions two-weekly. The following paragraphs describe
Table 1: Instruments at different assessment moments
M1 Week 0 M2 Week 5 M3 Week 10 M4 Week 22 M5 Week 52 After each 
session
ASI X X
BAI X X X X
BSI X X X X X
CGI-S/I X X
DAS-A-NL X
DQ X
EQ-5D X X X X
GAF X
HAq X X X
HDRS X X X X X
IDS-SR X X X X
LEIDS X X
MAS X X X
MINI-Plus X
OQ-45 X X X X
PMS X
TFBq X
TiC-P X X X
VAS X X X X
VKP X
ASI: Anxiety Sensitivity Index, BAI: Beck Anxiety Inventory, BSI: Brief Symptom Inventory, CGI-S/I: Clinical Global Impression Scale – Severity of Illness/Global 
Improvement, DAS-A-NL: Dysfunctional Attitude Scale, DQ: Demographic Questionnaire, EQ-5D: EuroQol, GAF: Global Assessment of Functioning Scale, 
HAq: Penn Helping Alliance Questionnaire Method, HDRS-17: Hamilton Depression Rating Scale, IDS-SR: Inventory of Depressive Symptomatology – Self-
Report, LEIDS: Leiden Index of Depression Sensitivity, MAS: Medication Adherence Scheme, MINI-Plus: Mini-International Neuropsychiatric Interview – Plus, 
OQ-45: Outcome Questionnaire, PMS: Psychological Mindedness Scale, TFBq: Penn Therapist Facilitating Behaviors Questionnaire, TiC-P: Trimbos/iMTA 
Questionnaire for Costs associated with Psychiatric Illness, VAS: Visual Analogue Scales, VKP: Questionnaire on Personality TraitsPage 4 of 14
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both therapies, the pharmacotherapy protocol, and the
therapists.
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy (CBT) was developed by
Beck [18] and is founded in the cognitive theory, which
states that information in the human brain is organized in
certain patterns, or schemata, that contain general knowl-
edge about the world and the person itself. These sche-
mata are used to select, reduce, and interpret information.
According to the cognitive theory, mental disorders are
caused and maintained by dysfunctional thought sche-
mata. Dysfunctional schemata express themselves in logi-
cal errors and dysfunctional automatic thoughts and give
rise to all sorts of emotional and behavioral problems.
Beck asserts that with depressive disorders, thinking in
general is preoccupied with loss and hopelessness. The so-
called depressive schemata are characterized by thoughts
about one's own worthlessness and guilt, the world's cold-
heartedness and injustice, and the future's desperateness.
The cognitive part of CBT aims at locating and correcting
the negative automatic thoughts and logical errors, and
changing the schemata, thereby alleviating the depressive
symptoms. Besides this cognitive element CBT contains a
behavioral part, which is based on the notion that depres-
sion is partly caused or maintained by a lack of pleasant
or satisfactory activities [19]. In CBT patients are therefore
encouraged to identify activities that affect their mood
positively and engage in these more often. CBT is further
characterized by a limited time span, a structured
approach, and the use of homework assignments.
The treatment protocol used in the present study is based
on a CBT research protocol for the treatment of depressive
and anxiety disorders [20], in which parts of the treatment
protocol described by Boelens & Bloedjes [21] were
adopted. The manual was rewritten solely for the purpose
of treating depressive disorders. The main alteration for
the current study is concerned with the emphasis on acti-
vation of the patient in the first treatment phase.
Cognitive Behavioral Therapy according to this protocol
starts with one introductory session, in which acquaint-
Participant flowchartFigure 2
Participant flowchart. CBT: Cognitive Behavioral Ther-
apy, SPSP: Short Psychodynamic Supportive Psychotherapy
Excluded (n=   ) 
Not meeting inclusion criteria (n=  )
Refused to participate (n=  ) 
Other reasons (n=   ) 
Assessed for eligibility (n= )
Enrollment 
Randomization 
Allocation 
Allocated to CBT (n=  )
Received allocated 
intervention (n=  ) 
Did not receive allocated 
intervention (n=   )  
For reason:
Lost to follow-up (n=  ) 
For reason: 
Discontinued intervention (n=)
For reason: 
Analyzed (n=    )
Excluded from analysis (n=) 
For reason: 
Follow-Up 
Analysis 
Allocated to SPSP (n=  )
Received allocated 
intervention (n=  ) 
Did not receive allocated 
intervention (n=   )  
For reason:
Lost to follow-up (n=  ) 
For reason: 
Discontinued intervention (n=)
For reason: 
Analyzed (n=    ) 
Excluded from analysis (n=) 
For reason: 
Research procedureFigure 1
Research procedure. CBT: Cognitive Behavioral Therapy, 
HDRS: Hamilton Depression Rating Scale, PT: Pharmacother-
apy, SPSP: Short Psychodynamic Supportive Psychotherapy
Week 10:     Assessment III – Treatment phase 
Exclusion: HDRS<14, not willing to 
sign informed consent, refusal to study 
randomization, exclusion criteria met. 
Exclusion: Depressive disorder not 
main diagnosis, use of antidepressant, 
exclusion criteria met.  
Intake Screening
Week 0:    Assessment I – Base line 
Randomization
CBT SPSP 
HDRS > 24 
SPSP + PT 
HDRS ≤ 24 
SPSP 
HDRS > 24 
CBT + PT 
HDRS ≤ 24 
CBT 
Week 5:     Assessment II – Treatment phase 
Week 52:     Assessment VI – Follow-up 
Week 22:     Assessment IV – Treatment end Page 5 of 14
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explained and a treatment contract is signed by both the
participant and the therapist. The CBT treatment itself
consists of three phases. The first phase (sessions 2–4)
focuses on the activation of the patient by means of plan-
ning and registering activities. In the second CBT phase
(sessions 5–7) the cognitive model and the principles of
cognitive therapy are explained. Patients keep a thought
diary to identify automatic thoughts. These thoughts are
challenged in the third phase (session 8–15), when they
are tested on their validity and utility by logical reasoning
together with the patient. Patients are encouraged to iden-
tify reasoning errors in their own thinking. In addition, a
behavioral experiment is designed and conducted to test
the identified automatic thoughts in real life. Depending
on the patient's needs, sessions 13 to 15 can be spent on
additional practice of basic challenging techniques, dis-
cussing complementary challenging techniques or paying
further attention to the behavioral experiments. The final
session (session 16) concludes treatment by evaluating
the therapy itself and the therapeutic goals set at the start
of treatment. When terminating the treatment, strategies
of action in case of relapse are discussed as well.
Short Psychodynamic Supportive Psychotherapy
Short Psychodynamic Supportive Psychotherapy was
developed as a treatment for depressed outpatients in the
early '90s by de Jonghe [5,6]. SPSP is rooted in six psycho-
analytical theories (described elsewhere [6]), which
together assume six innate, basic, social needs: sexuality,
aggression, the need to engage in relationships, and the
needs to be protected, loved, and esteemed. If these needs
are inadequately met in early infancy, they persist in
adults as ongoing malignant aspects of the internal rela-
tionships, acting as moulds on new external and internal
relationships. SPSP considers the gratification these needs
particularly relevant in the treatment of depressed
patients. The therapeutic action of SPSP consists in expe-
riencing 'relational dissonance' or friction between two
contradictory relationships simultaneously felt in the
therapeutic situation. One is determined by moulds
resulting from the past relationships, the other by the
present relationship with the therapist, in which the
patient will experience adequate gratification of his unmet
early infantile need. The proper gratification of unmet
developmental needs forms the psychoanalytical defini-
tion of 'support', which is considered the most important
curative factor in SPSP [6,22].
In general, psychodynamically oriented psychotherapies
can be placed on a supportive-expressive continuum.
SPSP can be regarded as situated within the supportive
half of this continuum. Psychodynamic therapies located
on the expressive end emphasize the interpretation of
transference. SPSP recognizes the existence of transference
but does not interpret it.
Specific to SPSP is the distinction of nine different levels
of discourse within the discussion of the problem area.
The levels 1, 2 and 3 successively focus on the patient's
physical and psychological symptoms and complaints,
the influence of life circumstances on the depressive
symptoms, and the influence of external interpersonal
relationships on the depressive symptoms. At the fourth
and fifth level the focus shifts to one or more relational
patterns in the patient's life and the patient's attitude in
life, respectively. The sixth level concerns how past rela-
tionships persist in the patient's current life, and the sev-
enth level regards the intrapersonal relationship the
patient maintains with himself or herself as a conse-
quence of identification with these past relationships. At
the eighth and ninth level the focus shifts to how the
problems discussed at levels 4–7 manifest themselves in
the relationship with the therapist. The levels of discourse
can vary considerably during the course of treatment [6].
As mentioned above, support is regarded as the most
important curative factor in SPSP. SPSP considers support
advancing progression and maturing behavior as ade-
quate, while regarding support advancing regression as
inadequate. The therapist explicitly shows a supportive
attitude by empathizing and being accepting, committed,
active, flexible, clear, definite, patient, and persistent. In
addition, the therapist systematically employs supportive
techniques, such as reducing guilt, shame and isolation,
clarifying, confronting, rationalizing, enhancing self-
esteem, advising, and modeling.
Short Psychodynamic Supportive Psychotherapy as
described by de Jonghe [23] constitutes the SPSP treat-
ment protocol in the present study. According to this pro-
tocol SPSP consists of three treatment phases. In the
starting phase the depressive complaints and their inter-
personal context are attended to, psycho-education about
depressive disorders is given, treatment aims are estab-
lished, and a treatment proposal is made. The second
phase is devoted to working on the treatment aims, which
usually relate to one of four interpersonal problem areas;
mourning, strife, role transformation or isolation. The
problem area is discussed according to the different dis-
course levels. If possible a connection is made between
the problems in this area and the internal relationships
(level 3 and up). Patients are encouraged to experience
their emotions and to reflect upon them. In addition
patients are encouraged to change their behavior and cog-
nitions, the consequences of which are discussed. The
final phase deals with the treatment termination and pos-
sible related mourning. The treatment aims are evaluated,
as well as the patient's perception of the treatment proc-Page 6 of 14
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attention is given to confirmation of the patient's inde-
pendence and handling of possible problems in the
future.
Pharmacotherapy
Pharmacotherapy is given according to a fixed three-stage
antidepressant protocol [24], which starts with the pre-
scription of the antidepressant Venlafaxine XR 75 mg/day.
This dose can be raised to reach the optimal medication
effect with steps of 75 mg/day at each session until a max-
imum of 375 mg/day. In cases of severe side effects or
inefficacy, Venlafaxine XR is decreased stepwise and Escit-
alopram is started at 10 mg/day without washout period.
This dose can be raised once by another 10 mg/day to
reach the optimal medication effect. In cases of severe side
effects or inefficacy, Escitalopram is decreased stepwise
and without washout period Nortriptyline 50 mg/day is
started. This antidepressant is monitored by means of
plasma levels (50–150 nanogram/l). In cases of severe
side effects or inefficacy of Nortriptyline, the patient is
considered as a study drop-out and treated outside the
trial according to care as usual within JMHC.
Pharmacotherapy starts with a first visit to the pharmaco-
therapist, in which information about the pharmacology
treatment is given, blood pressure is measured, and a
treatment proposal is made. Then Venlafaxine XR is pre-
scribed at a dose of 75 mg/day. For the first two weeks the
patient visits the psychiatrist weekly. This frequency is
reduced to two-weekly over the next six weeks and to
once-monthly afterwards. Extra visits can take place when
dose or medication are changed or whenever the psychia-
trist considers this necessary. As the study period takes 22
weeks, further pharmacology steps will usually not take
place during the trial phase.
Therapists
All pharmacotherapy therapists are either psychiatrists or
resident psychiatrists. Psychotherapists in both the SPSP
and CBT conditions are trained psychiatrists or psycholo-
gists, who all meet the educational criteria formulated by
the JMHC Depression Research Group according to guide-
lines of the Dutch professional associations of psycho-
therapists. SPSP therapists and CBT therapists participate
in one hour peer supervision groups on a two-weekly
basis, in which audio taped sessions are discussed. Resi-
dent psychiatrists receive supervision weekly.
Instruments
With regard to the instruments used in this study, primary
outcome measures, secondary outcome measures, meas-
ures of clinical predictors and additional measures can be
distinguished. The instruments include interviews, which
are conducted by independent assessors, and self-report
questionnaires, which are filled in by patients and thera-
pists. Table 1 represents the interviews and questionnaires
conducted at the different assessment moments.
Primary outcome measures
Primary outcome measures include the acceptability, fea-
sibility and efficacy of treatment.
Treatment acceptability and feasibility
Acceptability of treatment is measured by the number of
participants who refuse treatment when being randomly
allocated to it. Feasibility is assessed by the number of
patients terminating treatment prematurely.
Treatment efficacy
Treatment efficacy is measured by the decrease in depres-
sive symptoms according to three different sources: an
independent assessor, the patient, and the therapist.
Depression symptom severity according to the independ-
ent assessor is measured by means of the Hamilton Depres-
sion Rating Scale (HDRS-17) [14], which is a structured
interview designed to quantify the severity of depressive
symptoms in patients already diagnosed as suffering from
a depressive disorder. Its 17 items cover different depres-
sive symptoms, such as mood, sleep problems, lack of
appetite, weight loss, suicide intentions, and feelings of
guilt, which are rated on either a 0–2 or 0–4 scale. A psy-
chometric review of the scale [25] concludes that: "the
internal, interrater, and retest reliability for the overall
Hamilton depression scale are mostly good" and "estab-
lished criteria are met for convergent, discriminant, and
predictive validity". The HDRS-17 is scored according to
de Jonghe's scoring manual [26]. The independent asses-
sors are research employees who engage in one hour peer
supervision sessions two-weekly to promote interrater
reliability. In these sessions audio taped interviews are
discussed. If serious scoring problems arise, these are pre-
sented to the author of the Dutch scorings manual.
Depression severity from the patient's point of view is
assessed by means of the Inventory of Depressive Symptoma-
tology, Self-Report (IDS-SR) [27], which is a self-report
questionnaire designed to measure specific signs and
symptoms of depression in inpatients and outpatients.
The scale consists of 28 items in five dimensions: vegeta-
tive symptoms, cognitive changes, mood disturbance,
endogenous symptoms, and anxiety symptoms. Each of
the items is rated from 0 to 3 and is equally weighted in
the total score, which reflects the subjective severity of
depressive symptoms. The IDS-SR has a good internal
consistency, concurrent validity, and construct validity,
which allows its use in research [27-29]. Furthermore, it
has been proven to be sensitive to treatment effects in
depressed outpatients [29].Page 7 of 14
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clinician's perspective the Clinical Global Impression Scale
(CGI) [30] and the Global Assessment of Functioning Scale
(GAF) [16] are used. The CGI is a widespread primary out-
come measure in studies concerning the effectiveness of
psychiatric treatments. It provides a summary of an indi-
vidual's clinical functioning according to the therapist.
The CGI consists of two ratings: Severity of Illness (CGI-S)
at the moment of contact and Global Improvement (CGI-I)
of the patient from the start of treatment. Both use a
seven-step categorical scale "normal, not at all ill" (0) –
"among the most extremely ill patients" (7) and "very
much improved" (0) – "very much worse" (7), respec-
tively. Therapists rate the CGI-I after each treatment ses-
sion and the CGI-S after each session except for the first
one.
The clinician's view of the patient's more general func-
tioning is provided by means of the DSM-IV Axis V Global
Assessment of Functioning. The GAF rates psychological,
social, and professional functioning on a hypothetical
continuum (0–100) from mental health to mental disor-
der. Therapists rate this instrument after the sessions 1, 5,
10, and 16, corresponding with the patient assessment
moments.
Secondary outcome measures
Secondary outcome measures include general psychopa-
thology, general psychotherapy outcome, pain, health-
related quality of life, and cost-effectiveness.
General psychopathology
A shortened version of the Symptom Checklist 90 (SCL-90)
[31], the Brief Symptom Inventory (BSI) [32] is applied as a
measure of general psychopathology. The SCL-90 is the
most frequently used instrument in mental health care to
assess the nature and severity of psychopathology in
adults. With its 53 items the BSI is remarkably shorter
than the SCL-90, while conveying equal psychometric
properties. A recent Dutch translation has been shown to
have adequate reliability, good discriminant, and conver-
gent validity and to be sensitive to treatment effect. The
Brief Symptom Inventory assesses nine psychological symp-
tom dimensions: somatization, obsessive-compulsive,
interpersonal sensitivity, depression, anxiety, hostility,
phobic anxiety, paranoid ideation and psychoticism. Each
domain includes four to six items describing a complaint
or symptom. Subjects are asked to rate the occurrence of
this symptom in "the past week including today" on a
five-point Likert scale from 0 (not at all) to 4 (extremely).
In addition to the total scores on each dimension, the BSI
yields three general indices to indicate the general level of
psychological distress.
General psychotherapy outcome
General psychotherapy outcome is assessed using the Out-
come Questionnaire (OQ-45) [33,34], which was devel-
oped to convey three domains central to mental health:
symptom distress, interpersonal relations and social role
functioning. The self-report questionnaire consists of 45
items to be rated on a five-point Likert scale ranging from
0 (never) to 4 (almost always). Reliability and validity of
this instrument have been demonstrated [33,34].
Pain
To measure pain, numerical visual analogue scales (VAS)
[35] are used. Following Fava et al. [36] scores are
obtained on overall pain, headache, back pain, and shoul-
der pain. Respondents are asked to rate mean pain during
the last week on a scale from 0 (no pain at all) to 10 (worst
imaginable pain).
Health-related quality of life
The EuroQol (EQ-5D) [37] is a standardized, non-disease-
specific, self-report instrument for describing health
states. The EQ-5D questionnaire consists of 5 items cover-
ing the health dimensions: mobility, self care, usual activ-
ities, pain or discomfort, and anxiety or depression. The
items follow the general form: 1 = no problems, 2 = some
problems, 3 = extreme problems. In addition, a sixth item
is included as a global perception of health status using a
visual analogue scale ranging from 0 (worst imaginable
health state) to 100 (best imaginable health state). Valid-
ity and reliability of the EQ-5D have been investigated
and found to be acceptable [38-40].
Cost-effectiveness
Cost-effectiveness of both psychotherapies is evaluated
using the Trimbos/iMTA questionnaire for Costs associated
with Psychiatric Illness (TiC-P) [41]. The TiC-P is a self-
report questionnaire to assess health care costs (part I)
and costs resulting from production loss (part II) associ-
ated with psychiatric disorders. The 16 items of part I rate
the number of contacts with different health care institu-
tions within the last four weeks. Part II consists of the
Short Form Health and Labor Questionnaire (SF-HLQ) [42]
comprising three modules covering absence from paid
employment, production loss without absence from paid
employment, and impediments to paid or unpaid
employment.
Measurement of clinical predictors
Clinical predictors, that might distinguish patients who
benefit from either SPSP or CBT in particular, include
demographic variables, psychiatric symptoms, cognitive
and psychological characteristics, and the quality of the
therapeutic alliance.Page 8 of 14
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A self-designed demographic questionnaire (DQ) is used
to collect participants' demographic information. This
instrument consists of 13 questions concerning national-
ity, ethnic origin, marital status, living situation, religion,
education, occupation, and income.
Psychiatric symptoms
Concerning the clinical predictors of psychiatric symp-
toms, a distinction is made between depressive symp-
toms, comorbid anxiety symptoms and comorbid
personality pathology. Measurements of depressive com-
plaints include the HDRS-17, IDS-SR, CGI-I, CGI-S, and
GAF, which are described above.
The presence of anxiety symptoms is monitored by use of
the Beck Anxiety Inventory (BAI) [43], which is a self-report
inventory for measuring the severity of anxiety symptoms
in psychiatric patients. It includes 21 symptoms of anxi-
ety, the presence of each within the last week to be rated
on a four-point scale from 0 (not at all) to 3 (severely, I
could barely stand it). The BAI shows high internal con-
sistency and test-retest reliability, and evidence for its con-
vergent and discriminant validity has been found [43,44].
The presence of personality disorders is screened by the
Vragenlijst voor kenmerken van de Persoonlijkheid [Question-
naire on Personality Traits] (VKP) [45], which is a self-
report instrument for the assessment of personality disor-
ders based on the official World Health Organization
instrument for the diagnosis of DSM-III-R and ICD-10
personality disorders, International Personality Disorder
Examination (IPDE). The VKP consists of 174 items
divided over seven areas, for example, work, affect and
behavior, which concern the past 5 years and are scored
on a three-point scale: true (2), ? (1), and false (0). VKP
scores are moderately stable over time [45]. Because of the
2.5 time overestimation of the prevalence of personality
disorders compared to a semi-structured clinical interview
(IPDE), the VKP cannot be used as a diagnostic tool, but
it is considered suitable as a screening instrument for per-
sonality disorders [46].
Cognitive and psychological patient characteristics
The cognitive characteristics monitored as possible clini-
cal predictors of treatment effect include anxiety sensitiv-
ity, dysfunctional attitudes, and cognitive reactivity to sad
mood. In addition, psychological mindedness is assessed
as a possible predictive psychological patient characteris-
tic.
Anxiety sensitivity refers to a person's beliefs that anxiety
experiences have negative somatic, psychological or social
consequences. In the present study this concept is meas-
ured by means of the Anxiety Sensitivity Index (ASI) [47]. Its
16 items are scores on a scale from 1 (very little) to 5 (very
much). The ASI has been shown to have an acceptable
internal consistency, good test/retest reliability, and a
high degree of inter-item relatedness, although its factor
structure remains somewhat controversial [47-50]. More-
over, ASI scores have been proven to be stable over a 10
month time-frame within a group of psychiatric outpa-
tients with mood and anxiety disorders [50], and sensitive
to treatment with antidepressants in depressed outpa-
tients [51].
The Dutch version of the Dysfunctional Attitude Scale (DAS-
A-NL) [52] is used as a self-report measure for the pres-
ence and intensity of dysfunctional attitudes or depressive
suppositions, which are thought to constitute a vulnera-
bility for the development of a depressive disorder. Sub-
jects rate 40 statements regarding the way they usually
look upon matters on a seven-point scale from 1 (totally
agree) to 7 (totally disagree). The total score relates to the
severity of dysfunctional attitudes. Internal consistency of
this instrument is high and validity satisfactory [52].
The Leiden Index of Depression Sensitivity (LEIDS) [53] is a
self-report questionnaire that aims to measure cognitive
reactivity to sad mood, that is the relative ease with which
maladaptive cognitions or cognitive styles are triggered by
mild mood fluctuations. Participants are instructed to
imagine a sad mood defined as: "a score of 3 or 4 on a
scale of 0–10" and subsequently asked to rate 34 state-
ments regarding their thoughts and behavior during this
sad mood on a scale from 0 (not at all) to 5 (totally). The
LEIDS contains four subscales: negative self-evaluation,
acceptance/coping, indifference, and harm avoidance,
and has been found to have good psychometric properties
[53].
The Psychological Mindedness Scale (PMS) [54] is used in
this study to measure the concept of psychological mind-
edness; an ability to access one's own and other's feelings
and use these for changing behavior. Psychological mind-
edness as measured by this scale is generally regarded as a
measure of patients' suitability for dynamically orientated
psychotherapy. The scale contains 45 self-report items
scored on a 4-point scale ranging from 1 (strongly disa-
gree) to 4 (strongly agree). The PMS has good internal
consistency, and the total score has been found to be cor-
related with the number of psychotherapy sessions
attended by psychiatric patients [54-56].
Therapeutic alliance
Therapeutic alliance, or helping alliance, from the
patient's perspective is measured by means of the Penn
Helping Alliance Questionnaire Method (HAq) [57,58],
which assesses the extent to which the patient experiences
the therapist and the therapy as helpful. Therapeutic alli-Page 9 of 14
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of the Penn Therapist Facilitating Behaviors Questionnaire
(TFBq), which measures the degree to which the therapist
feels that he or she is helping the patient [58]. Both instru-
ments are part of the Penn Helping Alliance Scales, which
distinguish two types of helping alliance. Helping Alli-
ance Type 1 refers to the patient's perceived helpfulness of
the therapist, whereas Helping Alliance Type 2 is defined
as the patient's collaboration or bonding with the thera-
pist. The HAq and the TFBq are parallel self-report instru-
ments including 11 items; 8 relating to Helping Alliance
Type 1 and 3 relating to Type 2. Each item is rated on a 6-
point scale from -3 (No, I strongly feel that it is not true)
to 3 (Yes, I strongly feel that it is true). The total score
equals the sum of the item ratings. The Penn Helping Alli-
ance Scales show adequate overall reliability [59]. Thera-
peutic alliance, both in general [59] as well as measured
by the HAq and the TFBq in the early phases of treatment
[57], has been found to be correlated with psychotherapy
outcome.
Additional measures
In addition to the primary and secondary outcome meas-
ures and the instruments aimed at identifying clinical pre-
dictors of treatment effect, two instruments are included
in order to confirm the clinician's diagnosis of depressive
disorder and to monitor medication adherence. Addi-
tional measures also include a number of instruments
which are part of the standard monitoring procedure of
JMHC. These instruments will be used in secondary anal-
yses.
Diagnosis
In addition to the clinician's diagnosis the Mini-Interna-
tional Neuropsychiatric Interview – Plus (MINI-Plus) Sections
A: Major Depressive Episode and B: Dysthymic Disorder [17]
is conducted. The MINI-Plus is a clinician-rated structured
interview designed to diagnose psychiatric disorders
according to DSM-IV and ICD-10 criteria. Both sections
focus on current symptoms, and positive answering to
two screening questions is requisite to proceed to the
remaining questions concerning the complaints in more
detail. The MINI-Plus diagnostic interview is in wide-
spread use, because of its reliability and validity in diag-
nosing DSM-IV and ICD-10 psychiatric disorders in a
short time [17].
Medication adherence
Medication adherence is monitored at every assessment
moment for participants using antidepressants, by means
of the Medication Adherence Scheme (MAS). After having
explained that forgetting or not taking medication is com-
mon and that the information given will not reach the
pharmacotherapist, the independent assessor questions
the participant about the prescribed dose of antidepres-
sant and the amount not taken accidentally or on pur-
pose. Results are registered in the scheme, from which the
percentage of medication taken is calculated by dividing
the amount of medication taken by the total amount of
medication prescribed.
JMHC standard monitor instruments
The JMHC employs a routine monitor procedure for all its
patients in order to monitor treatment effects, with assess-
ment moments coinciding with the assessment moments
of the present study (week 0, week 22, and week 52). Data
from this standard procedure will be available to perform
secondary analyses on outcome measurement and clinical
predictors. The standard monitoring procedure covers the
areas of treatment requests, personality traits, coping
behavior, mastery, acculturation/discrimination, life
events and general satisfaction with mental health care.
The instruments include the Patient Request Form (PBV)
[60], Dutch MMPI short version (NVM) [61], the NEO Five
Factor Inventory subscales Neuroticism and Extraversion
(NEO-FFI) [62], Utrecht Coping Questionnaire subscales
Active Coping and Avoidant Coping (UCL) [63], the abbre-
viated Dutch version of the Personal Mastery Scale (PMS-
D) [64], the Lowlands Acculturation Scale (LAS) [65], the
List of Threatening Experiences (LTE) [66], and the Mental
Health Care Thermometer (MHCT) [67].
Randomization
Randomization is stratified into two gender groups
(male/female) and two age groups (<32.5/>32.5). The
independent research assessors perform the enrollment
and randomization of the patients. Randomization is exe-
cuted according to a list, the allocation sequence of which
was computer-generated by one of the researchers (JP).
Power
To detect a 15% difference in effectiveness between the
SPSP and CBT conditions with α = .05 and β = .80, 150
participants in each treatment condition are needed.
Analyses
Group differences will be investigated by chi-square tests,
an(c)ova, man(c)ova, and survival analyses. The analyses
will be performed according to the principles of intention
to treat and per protocol design. In addition, completer's anal-
yses will be conducted. Missing data will be replaced by
either the data of the last available measurement using the
principle of last observation carried forward, or by using
more sophisticated imputation techniques, for instance
multiple imputation or regression imputation.
The costs-utility ratio will be graphically represented in a
95%-confidence ellipse.Page 10 of 14
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robustness of the results under different conditions, vary-
ing the primary variables. Patient variables predicting
treatment outcome will be identified using multiple
regression analysis and logistic regression analysis.
Ethical principles
This study complies with the principles of the Helsinki
Declaration [68]. The design and execution of this study
were approved by the Dutch Union of Medical-Ethic Trail
Committees for mental health organizations.
Participation is voluntary and patients are informed that
they can withdraw their consent to participate at any time,
without any consequences for their further treatment. Par-
ticipants are informed about the research aims and
informed consent is obtained prior to the assessment of
patient eligibility.
Confidential information and patient names are treated
according to the medical confidentiality rules. Patient
data and patient details are stored in different files. All
study related documents and data are kept on the pro-
tected central server of JellinekMentrum Mental Health
Care, with access limited to members of the research team.
Discussion
This paper describes the study protocol of a randomized
controlled trial concerning Cognitive Behavioral Therapy
versus Short Psychodynamic Supportive Psychotherapy in
the outpatient treatment of depressive disorders. The aims
of this study are to compare both treatments in terms of
acceptability, feasibility and efficacy, and to identify clin-
ical predictors that distinguish patients that may benefit
from either of these treatments in particular.
The study design described above has specific strengths
and limitations. First of all, a strength of this study is that
both research aims relate to important matters in the treat-
ment of depressed outpatients. Concerning the first
research aim, there is a general paucity of studies regard-
ing the effectiveness of brief dynamic therapy in the treat-
ment of depression, limiting the evidence base of this
treatment method. More specifically, this study compares
two psychotherapy treatments, which have never been
directly compared before. To date, Short Psychodynamic
Supportive Psychotherapy has only been directly com-
pared to either pharmacotherapy or combined treatment
(SPSP and pharmacotherapy). In both respects, this study
relates to research questions unanswered so far. With
regard to the second aim, this study does not only assess
the effectiveness of the treatments, but it also hopes to
gain more insight into the question as to which type of
treatment will be most suitable for which type of patient.
Therefore the results of this study can be used in clinical
practice to improve the treatment allocation of patients.
Secondly, a strength of this trial is its strong external valid-
ity. Randomized clinical trials are often criticized for their
artificial treatment conditions, which make generalization
of the results difficult. In this study the external validity is
specifically attended to, resulting in outcomes that might
be directly relevant for clinical practice. The external valid-
ity is supported by the study's design, the outcome meas-
ures, the participant selection, and its multi centered
character. With regard to the design, this study uses a com-
parative strategy, which directly compares two fully real-
ized clinically representative treatment packages.
Participants receive psychotherapy treatment in a regular
outpatient clinic in the same way they would have
received it had they not been involved in the research
project. Therefore, the results of this study will directly
apply to the treatment in practice. Furthermore, the strong
external validity is reflected in the outcome measures. The
treatments are not only evaluated on efficacy, but accept-
ability and feasibility are also assessed. Both the latter are
important issues in the effectiveness of treatment in clini-
cal practice. In addition, the primary outcome measure,
reduction of depressive symptoms, is measured from
three different perspectives. Besides an independent
researcher (HDRS-17), the therapist (CGI-I/S and GAF)
and the patient (IDS-SR) rate the improvement, thereby
creating a full picture of the treatment effects. Finally,
external validity is supported by this trial's wide partici-
pant selection and multi centered character. Participants
are not specifically selected on their suitability for psycho-
therapy. Therefore, they represent a general population of
psychiatric patients rather than a selected group of
patients. By including patients from three different clinics
in different parts of the city, a heterogeneous population
is studied, contributing to the generalization of this
study's results.
A third strength of the present study consists in its regula-
tions to increase internal validity. Internal validity is pro-
moted by specific attention given to therapists' adherence
to the treatment protocol, the interrater reliability of the
main primary outcome measure, and the use of reliable
and valid instruments. Concerning the adherence to the
treatment protocol, internal validity is seen to by the
arrangements of fortnightly supervision groups for psy-
chotherapists in which audio taped sessions are discussed.
In addition, the interrater reliability of Hamilton Depres-
sion Rating Scale assessors are also specifically attended to
by two-weekly peer supervision groups, with scoring
problems being presented to the author of the Dutch scor-
ings manual. With regard to the measurement of outcome
and patients' characteristics, only widely used instrumentsPage 11 of 14
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study.
Regarding the limitations of this study three comments
must be made. In the first place, as noted earlier, the study
uses a comparative strategy, which directly compares two
fully realized clinically representative treatment packages.
Although this strategy is beneficial to the external validity,
it is impossible to identify specific operative aspects
within the treatment. Consequently, this study does not
focus on these aspects. In the second place, a limitation of
the current study is the absence of a control group or wait-
ing list condition. Besides the ethical considerations of
withholding patients from treatment for 22 weeks, it was
practically very difficult to incorporate such a condition
into this design. A third limitation is the fact that outcome
assessors are not blinded for treatment conditions.
Although blinding undoubtedly would have contributed
to the internal validity of this study, it is by definition
impossible to blind patients and therapists for psycho-
therapy treatment conditions. Because the independent
research assessors work in small-scale clinics, it was
impossible to prevent them from knowing the therapists'
treatment conditions. Therefore, the independent
research assessors could not be blinded. Nonetheless, sta-
tistical analyses will be performed blinded in order to
minimize the information bias effects.
Depression constitutes a major health care problem in
today's world. This study aims to contribute to the evi-
dence-based treatment of this disorder by further investi-
gating a potential promising form of psychotherapy. By
expanding the knowledge about cognitive behavioral ver-
sus psychodynamic treatment of depressive disorder, and
about which patients might benefit from one of these
treatments in particular, a still existing gap in knowledge
will hopefully be further filled.
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